

mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol Immunol.* 2011;8(2):110-120.

10. Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. *Nat Rev Microbiol.* 2021;19(2):77-94.

11. Lei W, Zhou K, Lei Y, et al. Gut microbiota shapes cancer immunotherapy responses. *NPJ Biofilms Microbiomes.* 2025;11(1):143.

12. Haider HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Eggerthella lenta*. *Science.* 2013;341(6143):295-298.

13. Roberts AB, Wallace BD, Venkatesh MK, et al. Molecular insights into microbial β -glucuronidase inhibition to abrogate CPT-11 toxicity. *Mol Pharmacol.* 2013;84(2):208-217.

14. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, et al. Mapping human microbiome drug metabolism by gut bacteria and their genes. *Nature.* 2019;570(7762):462-467.

15. Ruiz-Moreno AJ, Del Castillo-Izquierdo Á, Tamargo-Rubio I, et al. MicroBeRX: a tool for enzymatic-reaction-based metabolite prediction in the gut microbiome. *Microbiome.* 2025;13(1):78.

16. Okuda H, Ogura K, Kato A, et al. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. *J Pharmacol Exp Ther.* 1998;287(2):791-799.

17. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. *Cell Mol Life Sci.* 2001;58(5-6):737-747.

18. Hakkola J, Hukkanen J, Turpeinen M, et al. Inhibition and induction of CYP enzymes in humans: an update. *Arch Toxicol.* 2020;94(11):3671-3722.

19. Jourova L, Anzenbacher P, Lišková B, et al. Colonization by non-pathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice. *Folia Microbiol (Praha).* 2017;62(6):463-469.

20. Nieves KM, Hirota SA, Flannigan KL. Xenobiotic receptors and the regulation of intestinal homeostasis: harnessing the chemical output of the intestinal microbiota. *Am J Physiol Gastrointest Liver Physiol.* 2022;322(2):G268-G281.

21. Dvořák Z, Sokol H, Mani S. Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. *Trends Pharmacol Sci.* 2020;41(12):900-908.

22. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. *Drug Metab Rev.* 1997;29(4):1129-1188.

23. Puccetti M, Pariano M, Wojtylo P, et al. Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems. *Pharmaceutics.* 2023;15(2):506.

24. Recharla N, Geesala R, Shi XZ. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. *Nutrients.* 2023;15(10):2275.

25. Jourova L, Satka S, Frybortova V, et al. Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice. *Front Pharmacol.* 2022a;13:936013.

26. Jourova L, Anzenbacherova E, Dostal Z, et al. Butyrate, a typical product of gut microbiome, affects function of the AhR gene, being a possible agent of crosstalk between gut microbiome, and hepatic drug metabolism. *J Nutr Biochem.* 2022b;107:109042.

27. Matuskova Z, Anzenbacherova E, Vecera R, et al. Administration of a probiotic can change drug pharmacokinetics: effect of *E. coli* Nissle 1917 on amidarone absorption in rats. *PLoS One.* 2014;9(2):e87150.

28. Jourova L, Anzenbacher P, Matuskova Z, et al. Gut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiome. *Xenobiotica.* 2019;49(11):1296-1302.

29. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. *Gastrointest Endosc.* 2013;78(2):240-249.

30. Perez E, Lee CH, Petrof EO. A Practical Method for Pre-

paration of Fecal Microbiota Transplantation. *Methods Mol Biol.* 2016;1476:259-267.

31. Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. *Cell Host Microbe.* 2023;31(5):712-733.

32. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science.* 2018;359(6371):97-103.

33. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science.* 2018;359(6371):104-108.

34. Zhu C, Wang Y, Zhu R, et al. Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer. *Biomark Res.* 2024;12(1):56.

35. Xia L, Zhu X, Wang Y, et al. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect. *Cancer Lett.* 2024;598:217123.

36. Herman C, Bolyen E, Simard A, et al. Assessing microbiome engraftment extent following fecal microbiota transplant with q2-fmt. *PLoS Comput Biol.* 2025;21(7):e1013299.

37. Reynolds HM, Bettini ML. Early-life microbiota-immune homeostasis. *Front Immunol.* 2023;14:1266876.

38. Hudcovic T, Hermanova P, Kozakova H, et al. Priority order of neonatal colonization by a probiotic or pathogenic *Escherichia coli* strain dictates the host response to experimental colitis. *Front Microbiol.* 2024;15:1393732.

39. Estevinho MM, Yuan Y, Rodríguez-Lago I, et al. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. *United European Gastroenterol J.* 2024;12(7):960-981.

40. Jourová L, Anzenbacher P. Léky a mikrobiom. In: Tlaskalová-Hogenová Helena, Ekllová Danká a kol. (eds). *Mikrobiom a zdraví.* Praha: Grada; 2024. s. 372-381.

VÝHODY PRO LÉKAŘE DO 35 LET

SOLEN
MEDICAL EDUCATION



40%



Odborné časopisy
se slevou 40 %

1.

zdarma

První kongres
po ukončení studia **zdarma**

40%



Zvýhodněné
registrační **poplatky**
na většinu kongresů

Využijte své výhody na **www.solen.cz**